rizatriptan / Generic mfg. - LARVOL DELTA

Serotonin Syndrome With Quetiapine, Rizatriptan, Gabapentin, and Propranolol. (PubMed, Prim Care Companion CNS Disord) - No abstract available

Journal

Case report: Retinal involvement in recurrent painful ophthalmoplegic neuropathy with reversible color vision impairment (EHF-EHC 2025) - "Acute treatments (rizatriptan, ibuprofen, loxoprofen, rimegepant) failed; only indomethacin provided relief. Interictal IV nitroglycerin failed to induce migraine-like headache...By inhibiting cyclooxygenase (COX), indomethacin suppresses prostaglandin synthesis, reducing prostaglandin-mediated sensitization of trigeminovascular afferents, suggesting trigeminovascular afferent sensitization in RPON. Furthermore, RPON pathophysiology may involve retinal neuronal networks beyond the oculomotor nerve, supported by PERG amplitude changes implicating inner retinal layer pathology, indicating pathogenesis distinct from classical cranial neuropathies."

Case report • Clinical • CNS Disorders • Migraine • Neuralgia • Ophthalmology • Pain

Measurement and modeling of rizatriptan in supercritical CO2 for pharmaceutical processing. (PubMed, Sci Rep) - "The regular solution model produced the best results (AARD = 6.89%, R2 = 0.991). These results provide reliable data and simulation models that can improve supercritical carbon dioxide methodologies, and advance eco-friendly drug production strategies."

Journal • CNS Disorders • Migraine • Pain

Peripheral nerve blocks for chronic migraine: A case report on long term improvement following repeat multi-site injections (ASRA-FALL 2025) - "The Patient: A 30-year-old woman with a 10-year history of chronic migraines Mild Daily, constant, waxiing-and-waning, left-sided periorbital pressure Moderate-Severe Weekly left-sided periorbital, occipital, and temporal pressure with and without aura Prior preventative therapies Topiramate, nortriptyline, duloxetine, propranolol, CGRP monoclonal antibodies (inject), Gepants (oral) Abortive therapies Rizatriptan, Naratriptan Intervention: The Blocks Targets Greater and lesser occipital, auriculotemporal, supraorbital, supratrochlear nerves—identified via anatomical landmarks Injectate 0.5% bupivacaine without steroid Frequency/ Duration Every 3 months since 2023 at an outside facility, continued at VMMC 1 Symptoms Changes Migraine Characteristics Baseline Pre-Block 1 month Post-Block 3 months Post-Block Mild Migraine Average pain score (/10) 4.5 None 2.5 Duration Constant None Constant Days free of MILD migraine (per month) 0 30 0 Moderate-Severe Migraine Average..."

Case report • Clinical • Anesthesia • CNS Disorders • Migraine • Pain

A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy. (PubMed, J Pain Res) - "The report proportion varied among triptans, with naratriptan (12.23%) and almotriptan (12.15%) showing the highest rates, while sumatriptan (4.74%) had the lowest...Disproportionality analysis revealed significant signals for almotriptan (ROR=3.34), naratriptan (ROR=2.96), and rizatriptan (ROR=2.41), with almotriptan exhibiting the strongest association...Time-to-onset analysis showed frovatriptan had the earliest median onset (3.5 days), while almotriptan had the longest (284 days)...Clinicians should carefully evaluate cardiovascular risk factors before prescribing triptans and consider alternative treatments for susceptible individuals. Additional prospective studies are required to validate these findings."

Adverse events • Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Ischemic stroke • Migraine • Myocardial Infarction • Pain

Vestibular Migraine: Evidence, Updates, and Challenges (AAO-HNSF 2025) - "We will also cover results of several key trials from around the world, including the PROVEMIG trial in Germany that investigated metoprolol as a prophylactic agent, and a multicenter study of rizatriptan as an abortive agent. Both speakers have extensive experience with vestibular migraine, and we will share clinical pearls and educational materials to help audience members effectively treat these very common patients. An estimated 80% of vestibular migraine patients respond to treatment, and we hope to empower attendees to feel comfortable treating this population if they so choose.Learning Objectives: Learn how to use VM-PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) to measure disease severity in vestibular migraine.Understand the results of the INVESTMENT trial, showing the efficacy of anti-CGRP antibodies in the treatment of vestibular migraine.Develop a toolbox of evidence based approached for the diagnosis and treatment of vestibular..."

CNS Disorders • Migraine • Pain

Serotonergic Disinhibition Enables the Activation of the Ventrolateral Orbitofrontal Cortex to Ventrolateral Periaqueductal Gray Circuit to Effectively Induce Analgesic Effects in a Medication Overuse Mouse Model (IHC 2025) - "Methods Male C57BL/6J mice were used to establish a rizatriptan-induced MOH model through repeated drug administration...Conclusion This study demonstrates that chemogenetic activation of the glutamatergic vlOFC-vlPAG circuit in MOH mice has an analgesic effect. Moreover, the downregulation of the 5-HT1D receptor on glutamatergic neurons in the vlOFC of MOH mice promotes their spontaneous activation under pathological conditions, which can be further amplified by chemogenetic."

Preclinical • Migraine • FOS

Response to intravenous dihydroergotamine (DHE) for the treatment of refractory chronic migraine in adolescent patients (IHC 2025) - "Pre-infusion ondansetron 150 mcg/kg and prochlorperazine 5 mg/kg were administered PRN...For management, 54% (14/26) used sumatriptan,19% (5/26) used rizatriptan, 23% (6/26) used zolmitriptan, and 4% (1/26) used eletriptan. Preventively, 31% (8/26) had used propranolol, 23% (6/26) topiramate, 23% (6/26) amitriptyline, and 23% (6/26) pizotifen...This may include infusion slowing and increasing anti-emetic breadth and doses. Larger longer-term follow up studies are needed."

Clinical • CNS Disorders • Migraine

Galcanezumab-gnlm as an Effective Treatment for Chronic Migraine: A Case Report. (IHC 2025) - "Previous acute treatments included Neosaldina, Tramadol, Rizatriptan, SUMAXPRO (Sumatriptan + Naproxen), Dimenhydrinate, and Bromazepam. Preventive treatments included nortriptyline, cannabidiol, topiramate (200 mg/day, causing cognitive side effects such as memory lapses and difficulty completing sentences), and two cycles of OnabotulinumtoxinA (Botox), which provided temporary relief (15 and 7 days, respectively)...Monthly injections were maintained. Conclusion This case supports the efficacy and tolerability of galcanezumab-gnlm in a patient with chronic, treatment-resistant migraine, highlighting its value as a preventive therapeutic option."

Case report • Clinical • CNS Disorders • Migraine

Cephalalgia heterotopica: a case series of lower-half-face migraine (IHC 2025) - "One patient reported significant pain relief with rizatriptan and another with sumatriptan. Preventive treatment, including pizotifen, propranolol, flunarizine, amitriptyline, divalproex sodium, and pregabalin, proved to be effective...A proper case definition of this rare clinical presentation may provide new insights into understanding the mechanisms of migraine. Keywords: facial pain, migraine, lower-half-face migraine."

Clinical • CNS Disorders • Migraine

Pediatric Triptan-induced Reversible Cerebral Vasoconstriction Syndrome with Both Hemorrhagic and Ischemic Stroke: Case Report and Literature Review. (PubMed, NMC Case Rep J) - "Suspecting triptan-induced reversible cerebral vasoconstriction syndrome, rizatriptan was discontinued, and verapamil treatment was initiated. Triptans should be used with caution, as they may precipitate reversible cerebral vasoconstriction syndrome or exacerbate cerebral vasoconstriction. Careful monitoring and vascular imaging are essential for patients presenting with symptoms following triptan administration."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Migraine • Pain • Pediatrics • Subarachnoid Hemorrhage

A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data. (PubMed, Cephalalgia) - "Subgroup analyses showed similar trends for rimegepant versus specific triptans (rizatriptan: OR 2.49 [95% CI 2.33-2.67], and sumatriptan: OR 2.92 [95% CI 2.73-3.12]) and in patients with chronic migraine (OR 2.86 [95% CI 2.53-3.23]).ConclusionsThis study provides compelling evidence that rimegepant is associated with greater persistence than oral triptans for real-world acute treatment of migraine. Rimegepant is a favorable option for patients seeking effective and tolerable long-term treatment, particularly for those with insufficient response, intolerability, or contraindications to triptans."

Journal • Retrospective data • CNS Disorders • Migraine • Pain

India's Zim Laboratories up after getting marketing authorization for migraine drug in Australia (TradingView) - "Company receives marketing authorization from the Therapeutic Goods Administration (TGA) of Australia for its Rizatriptan oral strips, used to treat migraines"

ANDA • Migraine

Neuroinflammatory crosstalk in migraine: consolidated activity of rizatriptan and meloxicam in suppressing CGRP-induced nociception and COX-mediated inflammation. (PubMed, Inflammopharmacology) - "We have explored the molecular basis, pharmacological interaction, and clinical effectiveness of SYMBRAVO in this study, with a focus on how it can improve effectiveness, reduce adverse reactions and overcome barriers to single drug therapy. The results support a paradigm change towards integrated migraine therapy strategies that emphasize controlled, multi-pathway regulation."

Journal • Review • CNS Disorders • Inflammation • Migraine • Pain

Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis. (PubMed, J Pain Res) - "We conducted a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database from 2004-2024, focusing on adverse events associated with sumatriptan, rizatriptan, zolmitriptan, and almotriptan in patients aged 6-18 years. Age-stratified analysis revealed distinct profiles: younger children (6-11 years) showed higher risks for gastric emptying impairment (ROR=331.24) and throat tightness (ROR=77.14), while adolescents (12-18 years) experienced more diverse adverse events, notably pharyngeal swelling (ROR=133.81) and chest discomfort (ROR=19.05). Real-world triptan safety profiles reveal age-specific risks in pediatric populations, emphasizing the need for tailored monitoring strategies and age-appropriate safety protocols."

Adverse events • Journal • CNS Disorders • Migraine • Pain • Pediatrics • Respiratory Diseases

Efficacy and safety of rimegepant and other acute treatments in patients with migraine: An interim analysis from a national cross-sectional study in China (AHS 2025) - P=N/A | "The proportions of patients with pain freedom within 2 h after dosing was higher for rimegepant (50.0%) than for all other drugs (rizatriptan 20.3%, zolmitriptan 26.9%, ibuprofen 16.7%, loxoprofen 15.6%, diclofenac 15.0%, acetaminophen 23.0%, aminopyrine and caffeine tablets 19.1%,aminopyrine caffeine and calcium glycerophosphate tablets 28.6%, compound aminopyrine phenacetin 35.7%, EVE (main ingredients: ibuprofen, propyl urea, caffeine) 40.7%, paracetamol caffeine and aspirin powder 41.8%, Chinese herbal medicine: Yangjiao tablet 0.0%, Chinese herbal medicine: Zhengtian pill 9.5%, Chinese herbal medicine: decoction 0.0%). The findings of this study demonstrate that rimegepant outperforms some other acute treatment drugs in terms of overall therapeutic efficacy and has a low incidence of adverse reactions. This suggests that rimegepant may provide a more desirable therapeutic effect for patients. FIGURE."

Clinical • Observational data • CNS Disorders • Migraine • Pain

Case report: Atypical onset and recovery of Raynaud's phenomenon with galcanezumab with concurrent rizatriptan (AHS 2025) - "Galcanzeumab was discontinued and amitriptyline was started as preventative. Through initiation and discontinuation of galcanzeumab, the patient used rizatriptan as their abortive agent. It has been documented that triptans can also cause RP. The concurrent use of galcanzeumab and rizatriptan may have expedited the presentation of RP but did not affect recovery after discontinuation of only galcanzeumab."

Case report • Clinical • CNS Disorders • Depression • Migraine • Pain • Psychiatry

Induction of more severe central sensitization in a medication overuse headache model mice through active ingestion of rizatriptan. (PubMed, J Headache Pain) - "This study pioneers an ethologically valid MOH model that reflects more severe central sensitization and recapitulates active medication-seeking behaviour. PrL-mediated addiction-like-behaviour pathways and SPVC-centred nociceptive processing may play roles in the development of MOH. These findings provide novel neuromodulation targets (PrL, IC, SPVC) for refractory MOH management."

Journal • Preclinical • CNS Disorders • Migraine • Mood Disorders • Pain • Psychiatry • FOS

Rizatriptan vs Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial. (PubMed, JAMA Neurol) - P2/3 | "Findings do not support using rizatriptan for vestibular migraine attacks. ClinicalTrials.gov Identifier: NCT02447991."

Clinical • Journal • CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Histopathological effects of repeated 14-day administration of rizatriptan benzoate in a nitroglycerin-induced migraine rabbits model. (PubMed, Open Vet J) - "The current study successfully established a rabbit model of migraine using a single dose of NTG to induce migraine-like behavior. Moreover, pre-treatment with rizatriptan benzoate for fourteen days significantly reduced the symptoms of migraine and histopathological changes in different organs."

Journal • Preclinical • Review • CNS Disorders • Migraine • Pain

A Case Report of Calcitonin Gene-Related Peptide Antagonist as Treatment for Nummular Headache (AAN 2025) - "Non-steroidal anti-inflammatory drugs (NSAIDs), gabapentin, tricyclic antidepressants, and onabotulinum toxin A injections have been reported to be effective in small studies. This case highlights the CGRP antagonist medications as potential treatment options for severe or refractory nummular headache."

Case report • Clinical • CNS Disorders • Migraine • Pain

A Retrospective Cohort Study Comparing Persistence Between Rimegepant and Oral Triptans for the Acute Treatment of Migraine in the United States (AAN 2025) - "Patients from the rimegepant cohort were significantly more likely to be persistent than patients in the oral triptan cohort, likely reflecting better response, tolerability and/or treatment satisfaction associated with rimegepant compared to oral triptan treatment."

Retrospective data • CNS Disorders • Migraine • Pain

The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series analysis. (PubMed, Front Neurol) - "In our interrupted time-series analysis, the introduction of the gepants and lasmiditan was linked to decreases in triptan utilization, except for eletriptan which remained stable, and rizatriptan which rose at a slower rate...Our study suggests increased headache provider availability is associated with more prescriptions for naratriptan, eletriptan, and almotriptan. Additionally, the introduction of the gepants and lasmiditan broadly decreased the utilization of triptans. Critically, there was a strong association between a pharmaceutical company's, Pfizer, payments to physicians and utilization of their medication, rimegepant."

Journal • CNS Disorders • Migraine • Pain

Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-analysis. (PubMed, Pain Ther) - "In terms of treatment efficacy for MM, lasmiditan was not worse than different triptans and was even better than some of the triptans in the rate of sustained freedom from pain. As an emerging treatment, lasmiditan is promising for the treatment of MM. However, more research needs to be carried out because of the lack of safety analysis for lasmiditan."

Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain